John T. Santini, Jr., PhD


Dr. John Santini is a life science executive, serial entrepreneur, inventor, and scientist that has spent his career focused on the creation and growth of businesses developing next-generation pharmaceuticals, drug delivery systems, biosensors, and mobile health products. Prior to his current roles as CEO of Vergent Bioscience and co-founder/Board Member of ApoGen Biotechnologies (an Accelerator Life Science Partners’ portfolio company), Dr. Santini served in C-suite positions in four healthcare startups: MicroCHIPS, On Demand Therapeutics, RadioRx, and IRISense, closing nearly $100M in equity, license, and strategic transactions so far during his career. Dr. Santini has published in top scientific journals such as Nature, Nature Biotechnology, and Science Translational Medicine, has over 80 issued US and international patents, and his work resulted in a Technology Pioneer award from the World Economic Forum (Davos, Switzerland) as well as a Gold Medal from the Edison Awards in the Science and Medical, Game Changers category.

Dr. Santini received his PhD in chemical engineering from MIT as a National Science Foundation Fellow and his BSE in chemical engineering from the University of Michigan.